Alliance Global Partners lowered the firm’s price target on NeuroOne Medical to $3.15 from $3.33 and keeps a Buy rating on the shares. The firm cites a higher share count for the target drop following the company’s earnings report. The analyst believes NeuroOne continues to make progress on its programs.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NMTC:
- NeuroOne® Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
- Neuroone Medical Technologies Corporation (NMTC) Q1 Earnings Cheat Sheet
- NeuroOne® to Report First Quarter Fiscal Year 2024 Financial Results and Provide Corporate Update on February 13
- NeuroOne Medical price target raised to $3.33 from $2.20 at Alliance Global
- NeuroOne® Reports Fiscal Fourth Quarter and Full Fiscal Year 2023 Financial Results and Provides Corporate Update
